GSK’s Arexvy has become the first vaccine for respiratory syncytial virus (RSV) to be approved in the EU, getting the nod from the European Commission for use in older adults aged 60 or over.

Following this latest approval, Abrysvo has become the first and only RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU. The vaccine was approved for a similar ...

GSK looks set to bring the first vaccine for respiratory syncytial virus (RSV) to market in the EU, after its Arexvy shot was recommended for approval by the EMA’s human medicines committee.

making it the first shot greenlit for use in this age group to guard against RSV. Global vaccine and drugmaker GSK asked the FDA in February to expand approval beyond adults 60 and older ...

The European Commission (EC) has expanded the approval of Pfizer’s respiratory syncytial virus (RSV) vaccine ... The expanded EU approval follows a recommendation from the European Medicines ...

This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now offers in the EU the broadest RSV vaccine indication, which includes: Active immunization of individuals 18 ...

BRUSSELS, March 5. /TASS/. EU member states have all legal rights to procure Russian or Chinese coronavirus vaccines, but they themselves will shoulder the consequences of their use, European ...

will help bulk up EU vaccine supplies after a faltering rollout due to delivery delays from Pfizer and AstraZeneca. The first shipments will start in the second half of April, the company said ...